PTC Therapeutics, Inc.
PTC Therapeutics develops medicines for rare disorders globally. Products include Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi for conditions like Duchenne muscular dystrophy, SMA, and AADC deficiency. Pipeline products include Sepiapterin for phenylketonuria, PTC518 for Huntingtons disease, and vatiquinone/utreloxastat for Friedreich ataxia/Amyotrophic lateral sclerosis. The company distributes through third-party distributors. It has collaborations with various organizations.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (44.89) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EV/EBITDA (153.72) is significantly higher than the sector mean (85.60).
- EBITDA Margin (4.38%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 151.6 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 44.9 |